Aven‐mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma
- 9 March 2015
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 236 (3) , 348-359
Abstract
Conventional high‐grade osteosarcoma is the most common primary bone sarcoma, with relatively high incidence in young people. In this study we found that expression of Aven correlates inversely with metastasis‐free survival in osteosarcoma patients and is increased in metastases compared to primary tumours. Aven is an adaptor protein that has been implicated in anti‐apoptotic signalling and serves as an oncoprotein in acute lymphoblastic leukaemia. In osteosarcoma cells, silencing Aven triggeredG2cell‐cycle arrest; Chk1 protein levels were attenuated andATR–Chk1DNAdamage response signalling in response to chemotherapy was abolished in Aven‐depleted osteosarcoma cells, whileATM, Chk2 and p53 activation remained intact. Osteosarcoma is notoriously difficult to treat with standard chemotherapy, and we examined whether pharmacological inhibition of the Aven‐controlledATR–Chk1 response could sensitize osteosarcoma cells to genotoxic compounds. Indeed, pharmacological inhibitors targeting Chk1/Chk2 or those selective for Chk1 synergized with standard chemotherapy in2Dcultures. Likewise, in3Dextracellular matrix‐embedded cultures, Chk1 inhibition led to effective sensitization to chemotherapy. Together, these findings implicate Aven inATR–Chk1 signalling and point towards Chk1 inhibition as a strategy to sensitize human osteosarcomas to chemotherapy. Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 35 references indexed in Scilit:
- An Integrated Bioinformatics and Computational Biology Approach Identifies New BH3-Only Protein CandidatesThe Open Biology Journal, 2012
- Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?European Journal of Cancer, 2011
- Anticancer therapy with checkpoint inhibitors: what, where and when?Trends in Pharmacological Sciences, 2011
- Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xLEuropean Journal of Cancer, 2010
- Activation of ATR and related PIKKsCell Cycle, 2008
- Aven-Dependent Activation of ATM Following DNA DamageCurrent Biology, 2008
- DNA damage-induced activation of ATM and ATM-dependent signaling pathwaysDNA Repair, 2004
- Survivin and aven: two distinct antiapoptotic signals in acute leukemiasAnnals of Oncology, 2003
- Chk1 and Chk2 kinases in checkpoint control and cancerCancer Cell, 2003
- Aven, a Novel Inhibitor of Caspase Activation, Binds Bcl-xL and Apaf-1Molecular Cell, 2000